GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Everolimus overview
Everolimus (Afinitor, Votubia, RAD001) is an ester of the macrocytic immunosuppressive agent and acts as an anti-neoplastic agent. It is formulated as tablets for oral route of administration. It is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole, adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic, adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib, adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery, and for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
The drug candidate is under development for the treatment of endometrial cancer, diffuse large B-cell lymphoma, low grade glioma, high-grade glioma (HGG), medulloblastoma, CNS embryonal tumor, ependymoma, diffuse intrinsic pontine glioma (DIPG), metastatic castrate-resistant prostate cancer, radioiodine-refractory thyroid cancer (papillary, follicular, medullary Hurthle cell), peripheral nerve sheath tumor, acute lymphocytic leukemia, relapsed or refractory acute myelocytic leukemia, myelodysplastic syndrome. It was also under development for the treatment of metastatic renal cell carcinoma, HER2 positive breast cancer, hepatocellular carcinoma, gastric cancer, chronic myelocytic leukemia (chronic myeloid leukemia), gastrointestinal stromal tumor, glioblastoma multiforme, non-small cell lung cancer, myeloblastic syndrome, metastatic colorectal cancer, urothelial cell cancer, progressive intracranial meningioma, relapsed or refractory cutaneous T-cell lymphoma, relapsed and refractory seminomatous, non-seminomatous germ cell cancers and advanced nonfunctional neuroendocrine tumors of gastrointestinal or lung origin and cervical cancer advanced squamous cell carcinoma of head and neck, ovarian cancer, peritoneal cancer, fallopian cancer. It was also underdevelopment for bone or soft tissue sarcoma including liposarcoma, synovial sarcoma, vestibular schwannoma, malignant paraganglioma, fibrosarcoma, gastrointestinal stromal tumor, leiomyosarcoma, angiosarcoma including haemangiopericytoma, miscellaneous sarcoma including mixed mesodermal tumors of the uterus osteosarcoma, Ewing’s sarcoma, refractory, rhabdomyosarcoma, alveolar soft part sarcoma (ASPS) and Waldenstrom macroglobulinemia. It was also under development for the treatment of epilepsy in children with Sturge-Weber Syndrome (SWS).
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Everolimus’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.